Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

RB1 Polymorphism Contributes to the Efficacy of Platinum-Taxanes in Advanced Squamous Cell Lung Cancer

  • Liu, Di (Central Laboratory, Shanghai Pulmonary Hospital, Tongji University School of Medicine) ;
  • Xu, Wen (Central Laboratory, Shanghai Pulmonary Hospital, Tongji University School of Medicine) ;
  • Zhang, Zhi-Wei (Central Laboratory, Shanghai Pulmonary Hospital, Tongji University School of Medicine) ;
  • Qian, Ji (Fudan University Shanghai Cancer Center, State Key Laboratory of Genetic Engineering and MOE Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University) ;
  • Zheng, Hui (Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine) ;
  • Zhang, Jie (Department of oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine) ;
  • Su, Bo (Central Laboratory, Shanghai Pulmonary Hospital, Tongji University School of Medicine)
  • Published : 2015.02.25
Download PDF
⟨ Previous Next ⟩

Abstract

Background: RB1 (retinoblastoma 1) was reportedly one of the major determinative factors for sensitivity to taxanes in previous studies. In this study, we investigated the influence of RB1 single nucleotide polymorphisms (SNPs) on the efficacy of platinum-taxane regimens in advanced NSCLC patients. Materials and Methods: 234 cases of patients with advanced NSCLC who were treated with first-line platinum-taxane agents were enrolled in this study. Genomic DNA was extracted from patients' peripheral blood samples using a QIAamp DNA Maxi Kit, and genotyped by iSelect HD Bead-Chip. Results: Regression analyses were conducted through the univariate and multivariate Cox proportional hazards model in the 234 patients. The results showed that of the eight RB1 tagSNPs, only rs4151510 was a positive predictive factor for the advanced NSCLC patients treated with platinum taxanes regimen. The patients with G/G genotype of RB rs4151510 had longer overall survival (OS) than the non-G/G genotype (p=0.018). The histology was also correlated with OS in the whole advanced NSCLC patients. Three tagSNPs of RB1, rs4151510, rs4151465, rs9568036 were significantly associated with OS in the advanced NSCLC patients with squamous cell histology using Kaplan-Meier overall survival analysis stratified by histology. Conclusions: RB1 genomic variants were correlated with the efficacy of platinum-taxanes regimen. RB rs4151510 is an independent factor of the prognosis of NSCLC patients receiving platinum-taxane chemotherapy.

Keywords

References

  1. Chen W, Zheng R, Zhang S, et al (2013). Report of incidence and mortality in China cancer registries, 2009. Chin J Cancer Res, 25, 10-21.
  2. Contu SS, Contu PC, Damin DC, et al (2007). pRB expression in esophageal mucosa of individuals at high risk for squamous cell carcinoma of the esophagus. World J Gastroenterol, 13, 1728. https://doi.org/10.3748/wjg.v13.i11.1728
  3. De Laurentiis M, Cancello G, D'Agostino D, et al (2008). Taxane-based combinations as adjuvant chemotherapy of early breast cancer: A meta-analysis of randomized trials. J Clinical Oncol, 26, 44-53. https://doi.org/10.1200/JCO.2007.11.3787
  4. Dey B, Raphael V, Khonglah Y, et al (2014). Immunohistochemical Analysis of P53 and PRB in Esophageal Squamous Cell Carcinoma. J Clin Diagn Res, 8, 1-3. https://doi.org/10.1111/crj.12028
  5. Fabi A, Barduagni M, Ferraresi V, et al (2004). The combination of carboplatin and weekly paclitaxel: a safe and active regimen in advanced non small-cell lung cancer patients. A phase I-II study. J Exp Clin Cancer Res, 23, 25-32.
  6. Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917. https://doi.org/10.1002/ijc.25516
  7. Giacinti C, Giordano A (2006). RB and cell cycle progression. Oncogene, 25, 5220-7. https://doi.org/10.1038/sj.onc.1209615
  8. Hirabayashi M, Endoh K, Teramachi M, et al (2004). Phase II study of carboplatin and weekly paclitaxel combination chemotherapy in advanced non-small cell lung cancer: a Kansai Clinical Oncology Group study. Lung Cancer, 44, 355-62. https://doi.org/10.1016/j.lungcan.2003.12.001
  9. Julian LM, Palander O, Seifried LA, et al (2008). Characterization of an E2F1-specific binding domain in pRB and its implications for apoptotic regulation. Oncogene, 27, 1572-9. https://doi.org/10.1038/sj.onc.1210803
  10. Kurtyka CA, Chen L, Cress WD (2014). E2F inhibition synergizes with paclitaxel in lung cancer cell lines. PLoS One, 9, 96357. https://doi.org/10.1371/journal.pone.0096357
  11. Lee L-F, Li G, Templeton DJ, et al (1998). Paclitaxel (Taxol)- induced gene expression and cell death are both mediated by the activation of c-Jun NH2-terminal kinase (JNK/SAPK). J Biological Chemistry, 273, 28253-60. https://doi.org/10.1074/jbc.273.43.28253
  12. Manfredi JJ, Parness J, Horwitz SB (1982). Taxol binds to cellular microtubules. J Cell Biol, 94, 688-96. https://doi.org/10.1083/jcb.94.3.688
  13. Martinez-Cruz AB, Santos M, Lara MF, et al (2008). Spontaneous squamous cell carcinoma induced by the somatic inactivation of retinoblastoma and Trp53 tumor suppressors. Cancer Res, 68, 683-92. https://doi.org/10.1158/0008-5472.CAN-07-3049
  14. Milross CG, Mason KA, Hunter NR, et al (1996). Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J Natl Cancer Inst, 88, 1308-14. https://doi.org/10.1093/jnci/88.18.1308
  15. Ozkaya S, Findik S, Dirican A, et al (2012). Long-term survival rates of patients with stage IIIB and IV non-small cell lung cancer treated with cisplatin plus vinorelbine or gemcitabine. Exp Ther Med, 4, 1035-8.
  16. Rigas JR (2004). Taxane-platinum combinations in advanced non-small cell lung cancer: A review. Oncologist, 9, 16-23.
  17. Rozzi A, Nardoni C, Corona M, et al (2010). Weekly Regimen of Paclitaxel and Carboplatin as First-Line Chemotherapy in Elderly Patients with Stage IIIB-IV Non Small Cell Lung Cancer (NSCLC): Results of a Phase II Study. J Chemotherapy, 22, 419-23. https://doi.org/10.1179/joc.2010.22.6.419
  18. Schiff PB, Fant J, Horwitz SB (1979). Promotion of microtubule assembly in vitro by taxol. Nature, 277, 665-7. https://doi.org/10.1038/277665a0
  19. Suyama H, Igishi T, Sano H, et al (2004). ERK activation and subsequent RB phosphorylation are important determinants of the sensitivity to paclitaxel in lung adenocarcinoma cells. Int J Oncol, 24, 1499-504.
  20. van den Broek GB, Wildeman M, Rasch CR, et al (2009). Molecular markers predict outcome in squamous cell carcinoma of the head and neck after concomitant cisplatinbased chemoradiation. Int J Cancer, 124, 2643-50. https://doi.org/10.1002/ijc.24254
  21. Wang MT, Zhang JJ, Xu LY, et al (2013). Invasive and prognostic significance of pRB in esophageal squamous cell carcinoma: a meta-analysis. Dis Esophagus, 26, 723-8.
  22. Wang TH, Wang HS, Soong YK (2000). Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer, 88, 2619-28. https://doi.org/10.1002/1097-0142(20000601)88:11<2619::AID-CNCR26>3.0.CO;2-J
  23. Yamamoto Y, Shimizu E, Masuda N, et al (1998). RB protein status and chemosensitivity in non-small cell lung cancers. Oncol Rep, 5, 447-51.
  24. Zhao J, Zhang Z, Liao Y, et al (2014). Mutation of the retinoblastoma tumor suppressor gene sensitizes cancers to mitotic inhibitor induced cell death. Am J Cancer Res, 4, 42-52.